Project Grant W81XWH1510075

This federal Project Grant award, valued at $630,171.00, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The award aims to develop a first-in-class targeted radiopharmaceutical therapy (RPT) for the treatment of triple-negative breast cancer (TNBC), which lacks effective hormonal therapies. The key product being developed is a novel variable new antigen receptor (VNAR) binding domain from a nurse shark that targets the c-Met receptor,...

The Defense Health Agency awarded a $3,644,169 Project Grant to the ECOG-ACRIN Medical Research Foundation, Inc. to advance precision and equity in breast cancer care. This funding, provided through the Military Medical Research and Development program (CFDA 12.420), supports a 4-year clinical research extension to the TAILORx study, which aims to improve personalized treatment for breast cancer patients. As a subrecipient, the Foundation has also supported research at Dana-Farber Cancer...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research at the University of Texas MD Anderson Cancer Center to develop mathematical models and computational tools for optimizing the delivery of a transarterial ablative therapy for treating hepatocellular carcinoma (liver cancer). The $536,836 award will fund a multi-disciplinary research effort to formulate mathematical models that capture the complex physical and...

This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...

This $406,500 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel intratumoral delivery system by Absco Therapeutics, Inc. (Abscotx) to enhance solid tumor immunotherapy. The Oncolymer platform utilizes a thermoresponsive hydrogel and FDA-approved imaging agent to enable sustained, localized delivery of therapeutic agents like immune-sensitizing siRNA and the TLR7 agonist imiquimod. Preclinical studies have...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $703,540 to Brigham & Women's Hospital Inc. to develop and optimize treatments for head and neck cancer using an implantable microdevice technology. The project aims to validate the performance of this "lab-in-a-patient" microdevice in predicting patient response to immunotherapy and chemotherapy, as well as test pharmacodynamic properties of a...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,002,591.00 to Targepeutics, Inc. to determine the intratumoral drug distribution of the immunotoxin GB13 for the treatment of adult and pediatric brain cancers. The 3-year project aims to transform health care for Service Members and the American public through innovative and impactful biomedical research on medical solutions for the battlefield. The...

The National Cancer Institute awarded a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston. The goal of this 5-year research project is to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer, an aggressive form of the disease with limited treatment options. The project will explore using a small molecule drug conjugate that targets the prostate-specific membrane...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...